Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity

v3.21.1
Stockholders' Equity
12 Months Ended
Dec. 31, 2020
Stockholders' Equity Note [Abstract]  
Stockholders' Equity

Note 9. Stockholders’ Equity


Common Stock


Authorized Shares


The Company has 45,000,000 common shares authorized with a par value of $0.001 per share.


Issuance of Shares Pursuant to Conversion of Series A Preferred Stock


On July 17, 2019, we issued 65,789 shares of our common stock to a holder of our shares of Series A Convertible Preferred Stock upon the conversion of 25,000 of such shares of Series A Convertible Preferred Stock.


On September 9, 2019, we issued 200,000 shares of our common stock to a holder of our shares of Series A Convertible Preferred Stock upon the conversion of 76,000 of such shares of Series A Convertible Preferred Stock.


On September 16, 2019, we issued 43,081 shares of our common stock to a holder of our shares of Series A Convertible Preferred Stock upon the conversion of 16,371 of such shares of Series A Convertible Preferred Stock.


On September 16, 2019, we issued 108,422 shares of our common stock to a holder of our shares of Series A Convertible Preferred Stock upon the conversion of 41,200 of such shares of Series A Convertible Preferred Stock.


On September 25, 2019, we issued 73,156 shares of our common stock to the holders of Series A Convertible Preferred Stock in settlement of fees owed to such holders pursuant to the terms of such of the Series A Convertible Preferred Stock. The shares had a fair value of $250,000. 


On September 30, 2019, we issued 24,843 shares of our common stock to a former employee in settlement of litigation. The shares of common stock had a fair value of $75,000. 


On November 11, 2019 we issued 200,000 shares of our common stock to the holders of Series A Convertible Preferred Stock in settlement of fees owed to such holders pursuant to the terms of such of the Series A Convertible Preferred Stock. The shares had a fair value of $584,000. 


On November 20, 2019, we issued 25,000 shares of our common stock to a former employee in per the terms of a settlement agreement. The shares of common stock had a fair value of $73,250.


On December 5, 2019, we issued 50,000 shares of our common stock to a director as compensation. The shares of common stock had a fair value of $135,000.


On December 11, 2019 we issued 6,579 shares of our common stock to the holders of Series A Convertible Preferred Stock in settlement of fees owed to such holders pursuant to the terms of such of the Series A Convertible Preferred Stock. The shares had a fair value of $21,053. 


On December 23, 2019 we issued 9,211 shares of our common stock to the holders of Series A Convertible Preferred Stock in settlement of fees owed to such holders pursuant to the terms of such of the Series A Convertible Preferred Stock. The shares had a fair value of $26,343.


During January 2020, the Company issued 5,264 shares of common stock to a holder of its Series A Convertible Preferred Stock upon the conversion of 2,000 of such shares of Series A Convertible Preferred Stock.


During February 2020, the Company issued an aggregate of 172,369 shares of common stock to holders of its Series A Convertible Preferred Stock upon the conversion of an aggregate of 65,500 of such shares of Series A Convertible Preferred Stock.


During April 2020, the Company issued an aggregate of 1,043,935 shares of common stock to holders of its Series A Convertible Preferred Stock upon the conversion of an aggregate of 396,695 of such shares of Series A Convertible Preferred Stock.


During May 2020, the Company issued an aggregate of 51,316 shares of common stock to holders of its Series A Convertible Preferred Stock upon the conversion of an aggregate of 19,500 of such shares of Series A Convertible Preferred Stock.


During August 2020, the Company issued 13,158 shares of common stock to a holder of its Series A Convertible Preferred Stock upon the conversion of 5,000 of such shares of Series A Convertible Preferred Stock.


During October 2020, the Company issued 13,158 shares of common stock to a holder of its Series A Convertible Preferred Stock upon the conversion of 5,000 of such shares of Series A Convertible Preferred Stock.


Issuance of Shares to Current and Former Employees and Directors


On January 8, 2020, the Company issued 50,000 shares of common stock to a former employee per the terms of a settlement agreement.


On March 12, 2020, the Company issued 16,667 shares of common stock to an employee pursuant to a vesting schedule.


On April 15, 2020, the Company issued 3,913 shares of common stock to an employee pursuant to a vesting schedule.


On April 16, 2020, the Company issued 5,264 shares of common stock valued at $36,584.80 or $6.95 per share to a director pursuant to a vesting schedule.


On April 21, 2020, the Company issued 30,303 shares of common stock to a former employee pursuant to a vesting schedule.


On June 24, 2020, the Company issued 25,000 shares of common stock to an employee pursuant to a vesting schedule.


On August 25, 2020, the Company issued 87,255 shares of common stock valued at $142,226 to a former employee per the terms of a settlement agreement, settling $125,000 of accrued expenses and recorded a loss on settlement of $17,226.


Transfer of Common Stock to Consultants


On or about February 1, 2019, the Company’s founder and CEO as well as another shareholder transferred an aggregate of approximately 1,379,000 and 144,000 shares of common stock, respectively to certain consultants of the Company, of which approximately 983,000 and 144,000 shares of common stock, respectively were sold to consultants in exchange for promissory notes. The Company accounted for these share transfers as stock-based compensation expense based upon the Black-Scholes model as if these were stock option grants made by the Company. The Company used the following inputs in the Black-Scholes option pricing model, expected life of 5 years, risk-free interest rate of 2.51%, volatility 92% and dividend yield of 0%. As a result, the Company recognized approximately $3.6 million of stock-based compensation expense during the first quarter of 2019 related to these share transfers. Additionally, approximately 396,000 shares of common stock were transferred by the founder and CEO to contractors for no consideration. The Company accounted for these share transfers as stock-based compensation based upon the underlying common stock price of $4.37 as of the date of transfer. The Company recognized approximately $1.7 million of stock-based compensation expense related to these transfers during the first quarter of 2019.


Issuance of Shares Pursuant to Exercises of Common Stock Warrants


On April 14, 2020, a holder of common stock warrants exercised 7,000 warrants for a cash payment of, $38,570.


Issuance of Shares Pursuant to Cashless Exercises of Common Stock Warrants


During April 2020, holders of common stock warrants exercised an aggregate of 520,925 warrants using a cashless exercise into 321,155 shares of common stock.


During May 2020, holders of common stock warrants exercised an aggregate of 56,982 warrants using a cashless exercise into 26,034 shares of common stock.


During August 2020, holders of common stock warrants exercised an aggregate of 116,448 warrants using a cashless exercise into 68,715 shares of common stock.


Issuance of Shares Pursuant to Cashless Exercises of Stock Options


During April 2020, holders of common stock options exercised an aggregate of 105,028 options using a cashless exercise into 57,534 shares of common stock.


During August 2020, holders of common stock options exercised an aggregate of 55,263 options using a cashless exercise into 28,890 shares of common stock.


Issuance of Shares Pursuant to Settlement of Accounts Payable


On April 16, 2020, the Company issued 100,000 shares of common stock in full settlement of $640,517 of accounts payable. The shares had a fair value of $6.95 per share.


On May 12, 2020, the Company issued 104,567 shares of common stock in full settlement of $93,150 of accounts payable and recorded a loss on settlement of $509,160. The shares had a fair value of $5.76 per share.


On June 24, 2020, the Company issued 80,000 shares of common stock and warrants to purchase 100,000 shares of common stock, of which 50,000 shall be exercisable at $3.80 per share and the remaining 50,000 shall be exercisable at $5.80 per share, in each case for a term of 5 years, in connection with the termination of a consulting arrangement and in full settlement of any and all claims again the Company. The Company had previously accrued $195,000 in connection with this consulting arrangement. The stock had a fair value of $2.37 per share.


On August 27, 2020, the Company issued 17,000 shares of common stock valued at $40,800 in full settlement of $48,790 of accounts payable. The shares had a fair value of $2.20 per share. The Company recorded a gain on settlement of accounts payable of $7,990.


On September 10, 2020, the Company issued 140,000 shares of common stock valued at $806,400 in full settlement of $88,950 of accounts payable and recorded a loss on settlement of $717,450. The shares had a fair value of $5.76 per share.


Issuance of Shares for Equity Financing


On December 31, 2020, The Company issued 36,842 shares of common stock and 46,053 five year warrants to purchase shares of common stock at $4.00 per share pursuant to the prior receipt of $140,000 in equity financing.


Preferred Stock


Issuance of Series A Preferred Stock


On December 19, 2018, the Company authorized Series A Preferred Shares consisting of 900,000 authorized shares, with a par value of $0.001.


Equity Financing


During May 2020, the Company received $515,000 of a committed $565,000 from the sale of 135,527 shares of common stock (at a price of $3.80 per share) and warrants to purchase 169,409 shares of common stock, at an exercise price of $4.00 per share. As of December 31, 2020, the full amount has not been received and only $140,000 worth of the shares and warrants have been issued. The remaining $375,000 is included in equity financing within current liabilities on the consolidated balance sheet.


Stock Incentive Plan


In connection with Alliance’s acquisition of SCW FL Corp., the Company adopted Alliance’s Second Amended and Restated 2016 Equity Incentive Plan (“2016 Plan”). The 2016 Plan allows the Company to grant shares of the Company’s common stock to the Company’s directors, officers, employees and consultants. On January 30, 2019, the Alliance shareholders approved the amendment of the 2016 Plan to increase the number of shares of common stock available for issuance thereunder to 3,000,000 shares of common stock.


On February 13, 2019, the Board of Directors of the Company granted an aggregate of 425,000 restricted stock units (“RSUs”) under the 2016 Plan, of which an aggregate of 325,000 shares were granted to management and vest quarterly over the next three years, and of which 100,000 were issued to a consultant and vest quarterly over one year. Upon the effectiveness under the Securities Act of a registration statement on Form S-8 with respect to the shares covered by the 2016 Plan, these RSUs vest in twelve equal quarterly instalments, commencing on the grant date of February 13, 2019 and had a grant date fair value of approximately $2.7 million. The Company also granted an additional 525,000 RSUs which are subject to performance vesting, of which an aggregate of 225,000 shares were issued to management and 300,000 were issued to a consultant. The 225,000 shares issued to management were cancelled in April 2020, when the person’s employment with the Company terminated. Additionally, the board of directors awarded stock options under the 2016 Plan to each of the four independent board members to acquire an aggregate of 53,572 shares of the Company’s common stock and to an employee to acquire 25,000 shares. The stock options have a term of five years, an exercise price of $6.49 per share, vest quarterly over four quarters beginning on the grant date of February 13, 2019 and had a grant date fair value of $431,000. The Company determined the fair value of the stock options using the Black-Scholes model with the following inputs: expected life 10 years, risk-free interest rate 0.25%, dividend yield 0% and expected volatility 90%.


On December 5, 2019, the Company issued 50,000 RSU’s to a member of the board of directors. The RSU’s vested immediately and had a fair value of $135,000. Additionally, on December 10, 2019, the board of directors awarded stock options under the 2016 Plan to each of the three remaining independent directors to 50,000 shares of the Company’s common stock. The stock options have a term of five years, an exercise price of $2.64 per share, vest immediately on the grant date of December 10, 2019 and had a grant date fair value of $388,746. The Company determined the fair value of the stock options using the Black-Scholes model with the following inputs: expected life 10 years, risk-free interest rate 1.0%, dividend yield 0% and expected volatility 100%.


On June 28, 2019, the Company terminated the aforementioned consultant and reversed the stock-based compensation expense recognized during the first quarter 2019 totaling $162,250 as the consultant had not vested in any of the RSU’s.


On October 26, 2019, the employment of the Employee who received the 250,000 RSU’s on February 13, 2019, terminated and the remaining stock based compensation for the employee was cancelled as the employee had not vested in the shares.


The number of shares of the Company’s common stock that are issuable pursuant to warrant and stock option grants with time-based vesting as of and for the year ended December 31, 2019 are:


    Warrant Grants     Stock Option Grants     Restricted Stock Units  
    Number of
shares
subject to
warrants
    Weighted-
average
exercise
price per
share
    Number of
shares
subject to
options
    Weighted-
average
exercise
price per
share
    Number of
shares
subject to
restricted
stock units
    Weighted-
average
exercise
price per
share
 
Balance at December 31, 2018     236,825     $ 26.00       135,023     $ 7.70       -     $       -  
Granted     1,112,220       5.67       203,572       3.65       730,303       -  
Exercised     (11,075 )     5.51       -       -       -       -  
Cancelled/Forfeited     (26,054 )     5.51       -       -       (100,000 )     -  
Balance at December 31, 2019     1,311,916     $ 9.35       338,595     $ 5.96       630,303     $ -  
Exercisable at December 31, 2019     1,311,916     $ 9.35       226,095     $ 6.57       630,303     $ -  

The number of shares of the Company’s common stock that are issuable pursuant to warrant and stock option grants with time-based vesting as of and for the year ended December 31, 2020 are:


      Warrant Grants       Stock Option Grants       Restricted Stock Units  
      Number of
shares
subject to
warrants
      Weighted-
average
exercise
price per
share
      Number of
shares
subject to
options
      Weighted-
average
exercise
price per
share
      Number of
shares
subject to
restricted
stock units
      Weighted-
average
exercise
price per
share
 
Balance at December 31, 2019     1,311,916     $ 9.35       338,595     $ 5.26       630,303     $ -  
Granted     146,053       4.51       -       -       2,222,984       -  
Exercised     (681,619 )     5.57       (160,291 )     4.78       (77,234 )     -  
Expired     (103,891 )     35.54       (59,916 )     10.55                  
Cancelled/Forfeited     -       -       -       -       (475,000 )     -  
Balance at December 31, 2020     672,459     $ 8.09       118,388     $ 3.25       2,301,053     $ -  
Exercisable at December 31, 2020     672,459     $ 8.09       118,388     $ 3.25       2,301,053     $ -  

The Company has classified the warrant as having Level 2 inputs, and has used the Black-Scholes option-pricing model to value the warrant.  The fair value at the issuance dates for the above warrant was based upon the following management assumptions:


    Issuance dates    
Risk-free interest rate     1.00 – 1.69 %  
Expected dividend yield     0 %  
Expected volatility     100 %  
Term     5 years    
Fair value of common stock   $  1.51 - 2.37    

The Company’s outstanding warrants and options at December 31, 2020 are as follows:


Warrants Outstanding    

Warrants Exercisable

 
Exercise Price Range   Number
Outstanding
    Weighted Average
Remaining
Contractual Life (in
years)
    Weighted Average
Exercise Price
    Number
Exercisable
    Weighted
Average
Exercise Price
    Intrinsic Value  
$3.80 - $141.17     672,459       3.01     $ 8.09       672,459     $ 8.09       -  

Options Outstanding    

Options Exercisable

 
Exercise Price Range     Number
Outstanding
    Weighted Average
Remaining
Contractual Life (in
years)
    Weighted Average
Exercise Price
    Number
Exercisable
    Weighted
Average
Exercise Price
    Intrinsic Value  
  $2.64 - $6.84          118,388       3.69     $ 3.25       118,388     $ 3.25       -  

As of December 31, 2020 and 2019, the total unrecognized expense for unvested stock options and restricted stock awards was approximately $2.5 million and $3.2, respectively, to be recognized over a three-year period for restricted stock awards and one year for option grants from the date of grant.


Stock-based compensation expense for the years ended December 31, 2020 and 2019 was as follows:


    For the years ended December 31,  
    2020     2019  
Stock-based compensation expense   $ 3,284,570     $ 7,482,254  

Stock-based compensation expense categorized by the equity components for the years ended December 31, 2020 and 2019 is as follows:


   

For the years ended December 31,

 
    2020     2019  
Common stock   $ 3,169,470     $ 1,575,044  
Stock option awards     -       584,280  
Transfer of common stock by founders to contractors     115,100       5,322,930  
Total   $ 3,284,570     $ 7,482,254  

Stock compensation is included in general and administrative expenses on the consolidated statements of operations